로딩 중…
지수 로딩 중…
Y-Biologics
338840· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩13,270-5.62%
2026-06-19
Price Chart
Y-Biologics+26.74%
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 203.92B KRW |
| Revenue | 2.79B KRW |
| Net Income | -44.46B KRW |
| Total Assets | 53.91B KRW |
| Net Assets | 22.42B KRW |
| Employees | 60 |
| Value | |
| P/B | 9.10x |
| P/S | 73.15x |
| FCF Yield | -2.86% |
| Profitability | |
| ROE | -198.34% |
| ROA | -82.47% |
| Op. Margin | -332.51% |
| Revenue Growth | -30.77% |
| Financial Health | |
| Debt Ratio | 240.49% |
| Total Debt | 15.21B KRW |
| FCF | -5.84B KRW |
| Cash | 275.9M KRW |
| Current Ratio | 16.45x |
| Performance | |
| 1Y Return | 26.74% |
| 1M Return | -27.13% |
| From 52W High | -65.08% |
| 1Y MDD | -63.20% |
| Trading | |
| Volume | 87,677 shares |
| Foreign Own. | 1.75% |
| Per Share | |
| EPS | -2,961 KRW |
| BPS | 1,477 KRW |
Company Info
Y-BIOLOGICS, established in 2007 and listed on KOSDAQ in 2023, focuses on antibody drug research and development. The company leverages its antibody discovery and T-cell bispecific antibody platforms for new drug development, pursuing commercialization through technology transfer and contract research services with global pharmaceutical partners. It has also developed the Multi-AbKine platform for next-generation PD-1 new drugs, employing pH-sensitive antibody mechanism Antibody-Drug Conjugates (ADCs) to specifically target cancer cells.